Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.4.24.3 (
collagenase
)
18,340
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
To understand the role of tissue inhibitors of
metalloproteinase-1
and -2 (TIMP-1 and TIMP-2) in intraocular diseases, levels of TIMP-1 and TIMP-2 were measured by enzyme immunoassay in 47 patients with various ocular diseases: in subretinal fluid of 7 patients with rhegmatogenous retinal detachment and in vitreous of 12 patients with
proliferative diabetic retinopathy
, 4 with proliferative vitreoretinopathy, 2 with vitreous hemorrhage due to branch retinal vein occlusion, 12 with idiopathic macular hole, 3 with retinal detachment due to high-myopic macular hole, 4 with macular epiretinal membrane, and 3 with choroidal neovascular membrane due to age-related macular degeneration. TIMP-1 levels were significantly higher in subretinal fluid than in vitreous fluid with any diseases (P < 0.0001, Mann-Whitney U test). TIMP-1 levels in vitreous fluid of the eyes with
proliferative diabetic retinopathy
and proliferative vitreoretinopathy were higher than those in vitreous with other diseases (P < 0.0001). In contrast, TIMP-2 levels were not elevated in the subretinal fluid and vitreous. TIMP-1, but not TIMP-2, was secreted into the subretinal space in rhegmatogenous retinal detachment, and also into the vitreous in eyes with proliferative disease, suggesting that TIMP-1 would play a specific role in the process of these diseases.
...
PMID:TIMP-1 and TIMP-2 levels in vitreous and subretinal fluid. 982 66
To investigate which matrix metalloproteinases (MMPs) are more likely to be involved in the angiogenic process in
proliferative diabetic retinopathy
(
PDR
), we measured the levels of MMPs in the vitreous fluid from patients with
PDR
and controls and correlated these levels with the levels of vascular endothelial growth factor (VEGF). Vitreous samples from 32
PDR
and 24 nondiabetic patients were studied by mosaic multiplex MMPs enzyme-linked immunosorbent assay (ELISA), single ELISA, Western blot and zymography analysis. Epiretinal membranes from 11 patients with
PDR
were studied by immunohistochemistry.
MMP-8
and MMP-13 were not detected. ELISA, Western blot and gelatin ymography assays revealed significant increases in the expression levels of
MMP-1
, MMP-7, MMP-9 and VEGF in vitreous samples from
PDR
patients compared to nondiabetic controls, whereas MMP-2 and MMP-3 were not upregulated in vitreous samples from
PDR
patients. Significant correlations existed between ELISA and zymography assays for the quantitation of MMP-2 (r=0.407; p=0.039) and MMP-9 (r=0.711; p<0.001). Significant correlations were observed between levels of VEGF and levels of
MMP-1
(r=0.845; P<0.001) and MMP-9 (r=0.775; p<0.001), and between levels of
MMP-1
and MMP-9 (r=0.857; p<0.001). In epiretinal membranes, cytoplasmic immunoreactivity for MMP-9 was present in vascular endothelial cells and stromal monocytes/macrophages and neutrophils. Our findings suggest that among the MMPs measured,
MMP-1
and MMP-9 may contribute to the angiogenic switch in
PDR
.
...
PMID:Relationship between vitreous levels of matrix metalloproteinases and vascular endothelial growth factor in proliferative diabetic retinopathy. 2439 31